Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice

Neuropsychopharmacology

Volumn 37, Issue 7, 2012, Pages 1620-1631

  Klenotich, Stephanie J ^a   Seiglie, Mariel P ^a   McMurray, Matthew S ^b   Roitman, Jamie D ^b   Le Grange, Daniel ^a   Dugad, Priya ^a   Dulawa, Stephanie C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

activity based anorexia; anorexia nervosa; balb cJ; fluoxetine; olanzapine; survival

Indexed keywords

FLUOXETINE; OLANZAPINE;

ACTIVITY BASED ANOREXIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOOD INTAKE; LONG TERM CARE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; ANOREXIA; BENZODIAZEPINES; BODY WEIGHT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FEMALE; FLUOXETINE; MICE; MOTOR ACTIVITY; RUNNING; SEROTONIN UPTAKE INHIBITORS; SURVIVAL RATE;

EID: 84861193405     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.7     Document Type: Article

References (94)

1. Abler B, Erk S, Walter H (2007). Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study. Psychopharmacology (Berl) 191: 823-833. (Pubitemid 46355905)
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696. (Pubitemid 29517559)
3. Altemus M, Glowa JR, Galliven E, Leong YM, Murphy DL (1996). Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacol Biochem Behav 53: 123-131.
4. APA Diagnostic and Statistical Manual of Mental Disorders DSMIV- TR, 4th edn. American Psychiatric Association: Arlington, VA; (2000).
5. Arcelus J, Mitchell AJ, Wales J, Nielsen S (2011). Mortality rates in patients with anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. Arch Gen Psychiatry 68: 724-731.
6. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63-101. (Pubitemid 28026679)
7. Atchley DP, Eckel LA (2006). Treatment with 8-OH-DPAT attenuates the weight loss associated with activity-based anorexia in female rats. Pharmacol Biochem Behav 83: 547-553. (Pubitemid 43817125)
8. Attia E, Haiman C, Walsh BT, Flater SR (1998). Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 155: 548-551. (Pubitemid 28207453)
9. Audenaert K, Van Laere K, Dumont F, Vervaet M, Goethals I, Slegers G et al (2003). Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nucl Med 44: 163-169.
10. Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Mathis CA et al (2007a). Exaggerated 5-HT1A but normal 5-HT2A receptor activity in individuals ill with anorexia nervosa. Biol Psychiatry 61: 1090-1099. (Pubitemid 46551971)
11. Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Becker C et al (2007b). Serotonin transporter binding after recovery from eating disorders. Psychopharmacology (Berl) 195: 315-324.
12. Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Weissfeld L et al (2005). Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [carbonyl11C]WAY-100635. Arch Gen Psychiatry 62: 1032-1041. (Pubitemid 41248383)
13. Barbarich NC, McConaha CW, Gaskill J, La Via M, Frank GK, Achenbach S et al (2004). An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry 65: 1480-1482.
14. Beneke WM, Schulte SE, vander Tuig JG (1995). An analysis of excessive running in the development of activity anorexia. Physiol Behav 58: 451-457.
15. Bergen AW, van den Bree MB, Yeager M, Welch R, Ganjei JK, Haque K et al (2003). Candidate genes for anorexia nervosa in the 1p33-36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa. Mol Psychiatry 8: 397-406. (Pubitemid 36609664)
16. Bissada H, Tasca GA, Barber AM, Bradwejn J (2008). Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 165: 1281-1288.
17. Blier P (2003). The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 13: 57-66. (Pubitemid 36313278)
18. Boakes RA, Mills KJ, Single JP (1999). Sex differences in the relationship between activity and weight loss in the rat. Behav Neurosci 113: 1080-1089. (Pubitemid 30130882)
19. Brown KM, Bujac SR, Mann ET, Campbell DA, Stubbins MJ, Blundell JE (2007). Further evidence of association of OPRD1 & HTR1D polymorphisms with susceptibility to anorexia nervosa. Biol Psychiatry 61: 367-373. (Pubitemid 46131428)
20. Bulik CM, Slof-Op't Landt MC, van Furth EF, Sullivan PF (2007). The genetics of anorexia nervosa. Annu Rev Nutr 27: 263-275. (Pubitemid 351373358)
21. Burden VR, White BD, Dean RG, Martin RJ (1993). Activity of the hypothalamic-pituitary-adrenal axis is elevated in rats with activity-based anorexia. J Nutr 123: 1217-1225. (Pubitemid 23207046)
22. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96. (Pubitemid 26053226)
23. Couppis MH, Kennedy CH, Stanwood GD (2008). Differences in aggressive behavior and in the mesocorticolimbic DA system between A/J and BALB/cJ mice. Synapse 62: 715-724.
24. Davidson AJ, Stephan FK (1999). Feeding-entrained circadian rhythms in hypophysectomized rats with suprachiasmatic nucleus lesions. Am J Physiol 277: R1376-R1384.
25. Davis C, Woodside DB (2002). Sensitivity to the rewarding effects of food and exercise in the eating disorders. Compr Psychiatry 43: 189-194. (Pubitemid 34507466)
26. Delorme R, Betancur C, Wagner M, Krebs MO, Gorwood P, Pearl P et al (2005). Support for the association between the rare functional variant I425V of the serotonin transporter gene and susceptibility to obsessive compulsive disorder. Mol Psychiatry 10: 1059-1061. (Pubitemid 43251095)
27. Dennis K, Le Grange D, Bremer J (2006). Olanzapine use in adolescent anorexia nervosa. Eat Weight Disord 11: e53-e56. (Pubitemid 44049711)
28. Dixon DP, Ackert AM, Eckel LA (2003). Development of, and recovery from, activity-based anorexia in female rats. Physiol Behav 80: 273-279. (Pubitemid 37456764)
29. Duclos M, Gatti C, Bessiere B, Mormede P (2009). Tonic and phasic effects of corticosterone on food restriction-induced hyperactivity in rats. Psychoneuroendocrinology 34: 436-445.
30. Dulawa SC, Holick KA, Gundersen B, Hen R (2004). Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29: 1321-1330. (Pubitemid 38780655)
31. Dwyer DM, Boakes RA (1997). Activity-based anorexia in rats as failure to adapt to a feeding schedule. Behav Neurosci 111: 195-205. (Pubitemid 27097531)
32. Epling WF PW, Stefan L (1983). A theory of activity-based anorexia. Int J Eat Disord 3: 27-46. (Pubitemid 14210945)
33. Ferguson CP, La Via MC, Crossan PJ, Kaye WH (1999). Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int J Eat Disord 25: 11-17. (Pubitemid 29031304)
34. Fernstrom MH, Weltzin TE, Neuberger S, Srinivasagam N, Kaye WH (1994). Twenty-four-hour food intake in patients with anorexia nervosa and in healthy control subjects. Biol Psychiatry 36: 696-702. (Pubitemid 24358517)
35. Fineberg NA, Bullock T, Montgomery DB, Montgomery SA (1992). Serotonin reuptake inhibitors are the treatment of choice in obsessive compulsive disorder. Int Clin Psychopharmacol 7(Suppl 1): 43-47. (Pubitemid 23055861)
36. Frank GK, Bailer UF, Henry SE, Drevets W, Meltzer CC, Price JC et al (2005). Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11c]raclopride. Biol Psychiatry 58: 908-912. (Pubitemid 41790720)
37. Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C et al (2002). Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry 52: 896-906. (Pubitemid 35223433)
38. Fulton B, Goa KL (1997). Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53: 281-298.
39. Gelegen C, Collier DA, Campbell IC, Oppelaar H, van den Heuvel J, Adan RA et al (2007). Difference in susceptibility to activitybased anorexia in two inbred strains of mice. Eur Neuropsychopharmacol 17: 199-205. (Pubitemid 44779193)
40. Gelegen C, Pjetri E, Campbell IC, Collier DA, Oppelaar H, Kas MJ (2010). Chromosomal mapping of excessive physical activity in mice in response to a restricted feeding schedule. Eur Neuropsychopharmacol 20: 317-326.
41. Gelegen C, van den Heuvel J, Collier DA, Campbell IC, Oppelaar H, Hessel E et al (2008). Dopaminergic and brain-derived neurotrophic factor signaling in inbred mice exposed to a restricted feeding schedule. Genes Brain Behav 7: 552-559. (Pubitemid 351991493)
42. Harrison A, O'Brien N, Lopez C, Treasure J (2010). Sensitivity to reward and punishment in eating disorders. Psychiatry Res 177: 1-11.
43. Hebebrand J, Exner C, Hebebrand K, Holtkamp C, Casper RC, Remschmidt H et al (2003). Hyperactivity in patients with anorexia nervosa and in semistarved rats: evidence for a pivotal role of hypoleptinemia. Physiol Behav 79: 25-37. (Pubitemid 36734826)
44. Hillebrand JJ, van Elburg AA, Kas MJ, van Engeland H, Adan RA (2005). Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa? Biol Psychiatry 58: 651-657. (Pubitemid 41565580)
45. Holmes MM, Mistlberger RE (2000). Food anticipatory activity and photic entrainment in food-restricted BALB/c mice. Physiol Behav 68: 655-666. (Pubitemid 30182466)
46. Holtkamp K, Konrad K, Kaiser N, Ploenes Y, Heussen N, Grzella I et al (2005). A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. J Psychiatr Res 39: 303-310. (Pubitemid 40255915)
47. Honma K, von Goetz C, Aschoff J (1983). Effects of restricted daily feeding on freerunning circadian rhythms in rats. Physiol Behav 30: 905-913. (Pubitemid 13068317)
48. Hou Y, Wu CF, Yang JY, Guo T (2006). Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice. Prog Neuropsychopharmacol Biol Psychiatry 30: 1486-1495. (Pubitemid 44634955)
49. Jappe LM, Frank GK, Shott ME, Rollin MD, Pryor T, Hagman JO et al (2011). Heightened sensitivity to reward and punishment in anorexia nervosa. Int J Eat Disord 44: 317-324.
50. Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A et al (2006). Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 187: 222-228. (Pubitemid 44015616)
51. Kaye WH, Frank GK, McConaha C (1999). Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology 21: 503-506. (Pubitemid 29414794)
52. Kaye WH, Gwirtsman HE, George DT, Ebert MH (1991). Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch Gen Psychiatry 48: 556-562.
53. Kaye WH, Gwirtsman HE, George DT, Jimerson DC, Ebert MH (1988). CSF 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol Psychiatry 23: 102-105. (Pubitemid 18008093)
54. Kaye WH, Nagata T, Weltzin TE, Hsu LK, Sokol MS, McConaha C et al (2001). Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry 49: 644-652. (Pubitemid 32289359)
55. Klenotich SJ, Dulawa SC (2012). The activity-based anorexia mouse model. Methods Mol Biol 829: 377-393.
56. Kron L, Katz JL, Gorzynski G, Weiner H (1978). Hyperactivity in anorexia nervosa: a fundamental clinical feature. Compr Psychiatry 19: 433-440. (Pubitemid 9020240)
57. Leggero C, Masi G, Brunori E, Calderoni S, Carissimo R, Maestro S et al (2010). Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity. J Child Adolesc Psychopharmacol 20: 127-133.
58. McGurk SR, Lee MA, Jayathilake K, Meltzer HY (2004). Cognitive effects of olanzapine treatment in schizophrenia. Med Gen Med 6: 27.
59. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255. (Pubitemid 29272503)
60. Mistlberger RE (1994). Circadian food-anticipatory activity: formal models and physiological mechanisms. Neurosci Biobehav Rev 18: 171-195. (Pubitemid 24134487)
61. Mondraty N, Birmingham CL, Touyz S, Sundakov V, Chapman L, Beumont P (2005). Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry 13: 72-75. (Pubitemid 40514990)
62. Monteleone P, Maj M (2008). Genetic susceptibility to eating disorders: associated polymorphisms and pharmacogenetic suggestions. Pharmacogenomics 9: 1487-1520.
63. Mutlu O, Ulak G, Celikyurt IK, Akar FY, Erden F (2011). Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice. Pharmacol Biochem Behav 98: 398-404.
64. Newcomer JW (2007). Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68(Suppl 1): 20-27.
65. Ozaki N, Goldman D, Kaye WH, Plotnicov K, Greenberg BD, Lappalainen J et al (2003). Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry 8: 933-936. (Pubitemid 37421700)
66. Pare WP (1975). The influence of food consumption and running activity on the activity-stress ulcer in the rat. Am J Dig Dis 20: 262-273.
67. Paré WP VG, Isom KE, Reeves JM (1978). Sex differences and incidence of activity-stress ulcers in the rat. Psychol Rep 43: 591-594.
68. Pare WP, Vincent GP, Natelson BH (1985). Daily feeding schedule and housing on incidence of activity-stress ulcer. Physiol Behav 34: 423-429. (Pubitemid 15114614)
69. Perry PJ, Lund BC, Sanger T, Beasley C (2001). Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 21: 14-20. (Pubitemid 32096745)
70. Petrakis IL, Leslie D, Finney JW, Rosenheck R (2006). Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. Am J Addict 15: 44-49. (Pubitemid 43207188)
71. Pierce WD, Epling WF, Boer DP (1986). Deprivation and satiation: the interrelations between food and wheel running. J Exp Anal Behav 46: 199-210.
72. Powers PS, Santana CA, Bannon YS (2002). Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord 32: 146-154. (Pubitemid 34848184)
73. Pramyothin P, Khaodhiar L (2010). Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 17: 460-466.
74. Ratnovsky Y, Neuman P (2011). The effect of pre-exposure and recovery type on activity-based anorexia in rats. Appetite 56: 567-576.
75. Rosengarten H, Quartermain D (2002). The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three- and eighteen-monthold rats. Prog Neuropsychopharmacol Biol Psychiatry 26: 1047-1054. (Pubitemid 35256096)
76. Routtenberg A, Kuznesof AW (1967). Self-starvation of rats living in activity wheels on a restricted feeding schedule. J Comp Physiol Psychol 64: 414-421.
77. Santel S, Baving L, Krauel K, Munte TF, Rotte M (2006). Hunger and satiety in anorexia nervosa: fMRI during cognitive processing of food pictures. Brain Res 1114: 138-148. (Pubitemid 44414774)
78. Sayers SL, Campbell EC, Kondrich J, Mann SC, Cornish J, O'Brien C et al (2005). Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 193: 379-386. (Pubitemid 40800627)
79. Schlagenhauf F, Juckel G, Koslowski M, Kahnt T, Knutson B, Dembler T et al (2008). Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl) 196: 673-684.
80. Skarsfeldt T (1996). Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology (Berl) 124: 126-133.
81. Smelson DA, Ziedonis D, Williams J, Losonczy MF, Steinberg ML, Kaune M (2006). The efficacy of olanzapine for decreasing cueelicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 26: 9-12. (Pubitemid 43167083)
82. Sullivan PF (1995). Mortality in anorexia nervosa. Am J Psychiatry 152: 1073-1074.
83. Terry Jr AV, Hill WD, Parikh V, Evans DR, Waller JL, Mahadik SP (2002). Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology (Berl) 164: 360-368. (Pubitemid 35435711)
84. Theisen FM, Haberhausen M, Schulz E, Fleischhaker C, Clement HW, Heinzel-Gutenbrunner M et al (2006). Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects ofdose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit 28: 750-759. (Pubitemid 44967654)
85. Tortorici MA, Kochanek PM, Poloyac SM (2007). Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med 35: 2196-2204. (Pubitemid 47326460)
86. Verhagen LA, Luijendijk MC, Hillebrand JJ, Adan RA (2009). Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa. Eur Neuropsychopharmacol 19: 153-160.
87. Wagner A, Aizenstein H, Mazurkewicz L, Fudge J, Frank GK, Putnam K et al (2008). Altered insula response to taste stimuli in individuals recovered from restricting-type anorexia nervosa. Neuropsychopharmacology 33: 513-523.
88. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC et al (2006). Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA 295: 2605-2612. (Pubitemid 43882335)
89. Wang K, Zhang H, Bloss CS, Duvvuri V, Kaye W, Schork NJ et al (2011). A genome-wide association study on common SNPs and rare CNVs in anorexia nervosa. Mol Psychiatry 16: 949-959.
90. Watanabe K, Hara C, Ogawa N (1992). Feeding conditions and estrous cycle of female rats under the activity-stress procedure from aspects of anorexia nervosa. Physiol Behav 51: 827-832.
91. Wolff MC, Leander JD (2003). Comparison of the effects of antipsychotics on a delayed radial maze task in the rat. Psychopharmacology (Berl) 168: 410-416. (Pubitemid 36994024)
92. Woods DJ, Routtenberg A (1971). 00Self-starvation00 in activity wheels: developmental and chlorpromazine interactions. J Comp Physiol Psychol 76: 84-93.
93. Yokoyama F, Onozawa K, Kakui N, Imanishi T (2007). The selective serotonin reuptake inhibitor fluvoxamine suppresses post-feeding hyperactivity induced by food restriction in rats. Pharmacol Biochem Behav 87: 98-103. (Pubitemid 46855824)
94. Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC (2005). Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30: 1532-1538. (Pubitemid 41153125)